

JÃ¼rgen H E Kuball

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4270024/publications.pdf>

Version: 2024-02-01

141
papers

7,682
citations

66343

42
h-index

56724

83
g-index

152
all docs

152
docs citations

152
times ranked

9615
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 299-301.	2.4	8
2	Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 261-270.	2.4	9
3	The Role of $\gamma\delta$ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges. <i>Viruses</i> , 2022, 14, 117.	3.3	7
4	Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia. <i>European Journal of Haematology</i> , 2022, 108, 310-318.	2.2	0
5	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>OncImmunity</i> , 2022, 11, 2033528.	4.6	19
6	Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. <i>Blood Advances</i> , 2022, 6, 3378-3385.	5.2	45
7	Results of a multicenter phase I/II trial of TCR $\alpha\beta$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	2.4	27
8	Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study. <i>Annals of Hematology</i> , 2021, 100, 261-271.	1.8	8
9	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	3.7	7
10	Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT. <i>ELife</i> , 2021, 10, .	6.0	9
11	Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 397-418.	1.6	23
12	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
13	International Forum on Transfusion Practices in Haematopoietic Stem Cell Transplantation: Responses. <i>Vox Sanguinis</i> , 2021, 116, e25-e43.	1.5	0
14	International Forum on Transfusion Practices in Haematopoietic Stem Cell Transplantation: Summary. <i>Vox Sanguinis</i> , 2021, 116, 609-612.	1.5	1
15	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 76.	17.0	12
16	Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2651-2655.	2.4	2
17	Efficient lentiviral transduction method to gene modify cord blood CD8+ T cells for cancer therapy applications. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 357-368.	4.1	6
18	Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. <i>HemaSphere</i> , 2021, 5, e580.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2922-2928.	2.4	5
20	Characterization and modulation of anti-Î±Î²TCR antibodies and their respective binding sites at the Î²TCR chain to enrich engineered TÄcells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 388-400.	4.1	4
21	Î±Î² T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. <i>Blood Advances</i> , 2021, 5, 240-249.	5.2	21
22	Adding Help to an HLA-A*24:02 Tumor-Reactive Î³Î´TCR Increases Tumor Control. <i>Frontiers in Immunology</i> , 2021, 12, 752699.	4.8	2
23	Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. , 2021, 9, e003850.		20
24	Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 6140.	3.7	7
25	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
26	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2â€‰Gy) as conditioning prior to allogeneic stem cell transplantation in patients (â‰¥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 729-739.	2.4	4
27	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
28	Translating gammadelta (Î³Î´) T cells and their receptors into cancer cell therapies. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 169-184.	46.4	265
29	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). <i>Bone Marrow Transplantation</i> . 2020, 55, 681-694.	2.4	39
30	TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product. <i>Molecular Therapy</i> , 2020, 28, 561-571.	8.2	10
31	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
32	Editorial: Î³Î´ T Cells in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 602411.	4.8	2
33	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. <i>Current Opinion in Oncology</i> , 2020, 32, 427-433.	2.4	13
34	Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. <i>Bone Marrow Transplantation</i> , 2020, 55, 2188-2192.	2.4	9
35	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
36	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantationâ€”a retrospective study by the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1560-1569.	2.4	16

#	ARTICLE	IF	CITATIONS
37	A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1499-1509.	2.4	18
38	TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice. <i>Journal of Leukocyte Biology</i> , 2020, 107, 1069-1079.	3.3	9
39	Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. <i>Bone Marrow Transplantation</i> , 2020, 55, 1367-1378.	2.4	9
40	Î³ T-cell Receptors Derived from Breast Cancer Infiltrating T Lymphocytes Mediate Antitumor Reactivity. <i>Cancer Immunology Research</i> , 2020, 8, 530-543.	3.4	42
41	Î³ T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 4637-4651.	8.2	49
42	The connected worlds of stem cell transplantation and HIV. <i>Lancet HIV</i> , 2020, 7, e594-e595.	4.7	0
43	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140
44	Exploratory Study of Predicted Indirectly Recognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations. <i>Frontiers in Immunology</i> , 2019, 10, 880.	4.8	17
45	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
46	Evaluating in vivo efficacy and toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. , 2019, 7, 69.		42
47	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
48	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	2.4	129
49	Second autologous haematopoietic stem cell transplantation in systemic sclerosis—a case report. <i>Rheumatology</i> , 2019, 58, 1305-1307.	1.9	2
50	Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance. <i>HemaSphere</i> , 2019, 3, e285.	2.7	5
51	Tyrosine kinase inhibitor levels matter in treating chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019, 54, 1141-1144.	2.4	1
52	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. <i>Blood</i> , 2019, 133, 1457-1464.	1.4	125
53	Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 627-637.	3.5	41
54	Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion. , 2019, , 443-448.		6

#	ARTICLE	IF	CITATIONS
55	Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization. , 2019, , 69-74.		2
56	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S57.	2.0	0
57	Early Reconstitution of NK and Î³Î´ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1152-1162.	2.0	56
58	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. <i>Bone Marrow Transplantation</i> , 2018, 53, 1201-1205.	2.4	10
59	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
60	G-CSF Treatment Further Impairs T-Cell Reconstitution in Patients with Residual Anti-Thymocyte Globulin Exposure after Hematopoietic Cell Transplantation: Implications for G-CSF Use?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S37.	2.0	0
61	Individualized Fludarabine Dosing for Predictable Immune Reconstitution and Increased Survival Chances after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S306-S307.	2.0	1
62	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
63	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
64	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
65	Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. <i>Oncolmmunology</i> , 2018, 7, e1434465.	4.6	54
66	Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. <i>Bone Marrow Transplantation</i> , 2018, 53, 1255-1262.	2.4	13
67	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VÎ³9VÎ´2-T cells. <i>Oncolmmunology</i> , 2018, 7, e1375641.	4.6	61
68	Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design. <i>Journal of Clinical Oncology</i> , 2018, 36, 1175-1176.	1.6	10
69	Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. <i>Blood Advances</i> , 2018, 2, 565-574.	5.2	19
70	Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 389.	4.8	49
71	GMP-Grade Manufacturing of T Cells Engineered to Express a Defined Î³Î´TCR. <i>Frontiers in Immunology</i> , 2018, 9, 1062.	4.8	53
72	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61

#	ARTICLE	IF	CITATIONS
73	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. <i>Blood</i> , 2018, 132, 604-604.	1.4	3
74	Abstract LB-104: Targeting solid malignancies with TEGs: Î±Î²T cells engineered to express a defined Î³Î±TCR in xenograft mice model. , 2018, , .		0
75	First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors. <i>Blood</i> , 2018, 132, 2164-2164.	1.4	0
76	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. <i>Hepatology</i> , 2017, 65, 2074-2089.	7.3	7
77	Haematopoietic stem cell transplantation for autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2017, 13, 244-256.	8.0	108
78	Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem-Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S107-S108.	2.0	0
79	High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S72-S73.	2.0	2
80	Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S45-S46.	2.0	0
81	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haematopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. <i>Lancet Haematology</i> ,the, 2017, 4, e183-e191.	4.6	154
82	Prevention of VÎ³9VÎ²2 T Cell Activation by a VÎ³9VÎ²2 TCR Nanobody. <i>Journal of Immunology</i> , 2017, 198, 308-317.	0.8	9
83	NK Cells and Î³Î±T Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Current Stem Cell Reports</i> , 2017, 3, 301-311.	1.6	13
84	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcÎ³RI Reduce Immune Complex Binding and Downstream Effector Functions. <i>Journal of Immunology</i> , 2017, 199, 2432-2439.	0.8	8
85	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
86	Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. <i>Theranostics</i> , 2017, 7, 1705-1718.	10.0	13
87	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
88	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	1.4	0
89	Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2016, 14, 230.	4.4	27
90	RhoB Mediates Phosphoantigen Recognition by VÎ³9VÎ²2Î±T Cell Receptor. <i>Cell Reports</i> , 2016, 15, 1973-1985.	6.4	112

#	ARTICLE	IF	CITATIONS
91	Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 593-604.	8.0	81
92	Cytomegalovirus Status and the Outcome of T Cellâ€“Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1883-1887.	2.0	15
93	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016, 9, 118.	17.0	50
94	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	1.4	66
95	The next step toward GMP-grade production of engineered immune cells. <i>Oncolmmunology</i> , 2016, 5, e1076608.	4.6	2
96	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	1.4	10
97	Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition. <i>Blood</i> , 2016, 128, 4565-4565.	1.4	2
98	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	1.4	1
99	High CD34+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia â€” an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	1.8	53
100	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 3374-3374.	1.4	0
101	Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1839-1845.	2.0	21
102	Orchestrating an immune response against cancer with engineered immune cells expressing Î±Î²TCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 893-902.	4.2	12
103	Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3957-3968.	7.0	30
104	Immune Reconstitution and Clinical Outcome after Î±Î² T-Cell Depleted Allogeneic Stem Cell Transplantation from Matched Related and Unrelated Donors. <i>Blood</i> , 2015, 126, 4313-4313.	1.4	1
105	Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients. <i>Blood</i> , 2015, 126, 858-858.	1.4	3
106	Treatment of Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition. <i>Blood</i> , 2015, 126, 1939-1939.	1.4	0
107	Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease. <i>Chimerism</i> , 2014, 5, 94-98.	0.7	7
108	Cancer Immunotherapy Using ÄŹÄŹÄŹÄŹÄŹ T Cells: Dealing with Diversity. <i>Frontiers in Immunology</i> , 2014, 5, 601.	4.8	40

#	ARTICLE	IF	CITATIONS
109	Indirectly Recognized HLA-C Mismatches and Their Potential Role in Transplant Outcome. <i>Frontiers in Immunology</i> , 2014, 5, 210.	4.8	21
110	Refinement of the Definition of Permissible HLA-DPB1 Mismatches with Predicted Indirectly ReCognizable HLA-DPB1 Epitopes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1705-1710.	2.0	31
111	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	3.5	36
112	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	1.6	392
113	Multifunctional Î³Î± T cells and their receptors for targeted anticancer immunotherapy. <i>OncImmunology</i> , 2013, 2, e23974.	4.6	11
114	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human Î³Î± T-cell subset. <i>Blood</i> , 2012, 120, 2269-2279.	1.4	443
115	Î³Î± and Î±2CDR3 domains regulate functional avidity of T cells harboring Î³Î±2TCRs. <i>Blood</i> , 2012, 120, 5153-5162.	1.4	74
116	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012, 119, 1599-1606.	1.4	254
117	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. <i>Nature Medicine</i> , 2012, 18, 807-815.	30.7	398
118	Redirecting Î±Î±T cells against cancer cells by transfer of a broadly tumor-reactive Î³Î±T-cell receptor. <i>Blood</i> , 2011, 118, 50-59.	1.4	184
119	The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. <i>Haematologica</i> , 2011, 96, 1380-1384.	3.5	18
120	Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 161-171.	4.2	67
121	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. <i>Blood</i> , 2011, 118, 667-667.	1.4	1
122	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40â€“60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. <i>Blood</i> , 2011, 118, 159-159.	1.4	1
123	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2011, 118, 3046-3046.	1.4	0
124	Coexpression of the T-cell receptor constant Î± domain triggers tumor reactivity of single-chain TCR-transduced human T cells. <i>Blood</i> , 2010, 115, 5154-5163.	1.4	48
125	Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission. <i>Blood</i> , 2010, 116, 367-367.	1.4	2
126	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. <i>Blood</i> , 2010, 116, 3764-3764.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Increasing functional avidity of TCR-redirected T cells by removing defined <i>N</i>-glycosylation sites in the TCR constant domain. <i>Journal of Experimental Medicine</i> , 2009, 206, 463-475.	8.5	132
128	Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 579-591.	3.1	14
129	Molecular Design of the CÎ±Î² Interface Favors Specific Pairing of Introduced TCRÎ±Î² in Human T Cells. <i>Journal of Immunology</i> , 2008, 180, 391-401.	0.8	87
130	Facilitating matched pairing and expression of TCR chains introduced into human T cells. <i>Blood</i> , 2007, 109, 2331-2338.	1.4	318
131	Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. <i>Blood</i> , 2007, 110, 201-210.	1.4	383
132	Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2â€“11-mediated immune evasion. <i>Journal of General Virology</i> , 2007, 88, 1429-1439.	2.9	29
133	Cytomegalovirus Interleukin-10 Expression in Infected Cells Does Not Impair MHC Class I Restricted Peptide Presentation on Bystanding Antigen-Presenting Cells. <i>Viral Immunology</i> , 2006, 19, 92-101.	1.3	19
134	Redirection of T Cells by Delivering a Transgenic Mouse-Derived MDM2 Tumor Antigen-Specific TCR and its Humanized Derviative Is Governed by the CD8 Coreceptor and Affects Natural Human TCR Expression. <i>Immunologic Research</i> , 2006, 34, 67-87.	2.9	43
135	Designing TCR for Cancer Immunotherapy. , 2005, 109, 229-256.		14
136	Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. <i>Immunity</i> , 2005, 22, 117-129.	14.3	136
137	Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions. <i>Transplantation</i> , 2004, 78, 1774-1779.	1.0	28
138	Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation. <i>Journal of Clinical Oncology</i> , 2002, 20, 957-965.	1.6	112
139	Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer: Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 1750-1758.	1.6	201
140	Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. <i>Nature Immunology</i> , 2001, 2, 962-970.	14.5	348
141	Î³Î² T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3Î³ Repertoire of Healthy Adults. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1